Endocrinopathies induced by immune check point inhibitors. Optimal patient management tactics


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The objective of this review is to summarize the current experience in the management of various complications from the endocrine system in cancer patients who receive immune checkpoint inhibitors. Rational modern immunotherapy of oncological diseases can significantly increase the life expectancy and quality of life of patients. At the same time, the development of a wide range of immune-mediated side effects resulting from dysregulation of the immune system significantly worsens treatment outcomes. Immune checkpoint inhibitors can cause dysfunction of the endocrine glands - thyroid, pituitary, adrenal glands and pancreas, as well as their combined damage. The review discusses the prevalence of endocrinopathies, their early diagnosis in the treatment with various immune checkpoint inhibitors, algorithms for the treatment of endocrinopathies, which allow to increase the life expectancy of patients with malignant neoplasms and can be used by practicing endocrinologists in their daily practice.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Larisa Khamnueva

Irkutsk State Medical University

Email: hamnueval@mail.ru
Dr. Sci. (Med.), Professor, Head of the Department of Endocrinology, Clinical Pharmacology and Immunology 1, Krasnogo Vosstaniya str., Irkutsk 664003, Russian Federation

K. Sergeeva

Irkutsk State Medical University

Irkutsk, Russia

L. Andreeva

Irkutsk State Medical University

Irkutsk, Russia

A. Davydova

Irkutsk State Medical University

Irkutsk, Russia

Әдебиет тізімі

  1. Illouz F., Briet C., Cloix L., et al. Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists. Cancer Med. 2017;6(8):1923-29. doi: 10.1002/cam4.1145.
  2. Gonzàlez-Rodrfguez E., Rodrfguez-Abreu D. Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events. Oncologist. 2016;21(7):804-16. Doi: 10.1634/ theoncologist.2015-0509.
  3. Barroso Sousa R., Barry W.T., Garrido-Castro A.C., et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis. JAMA. Oncol. 2018;4(2):173-82. doi: 10.1001/jamaoncol.2017.3064.
  4. Tan M.H., Ravi I., Mizokami-Stout K., et al. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports. Clin Diabet. Endocrinol. 2019;5:1. doi: 10.1186/s40842-018-0073-4.
  5. Dillard T., Yedinak C.G., Alumkal J., et al. Anti-CTIA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary. 2010;13(1):29-38. doi: 10.1007/s11102-009-0193-z.
  6. Yang J.C., Hughes M., Kammula U., et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007; 30(8):825-30.
  7. Blansfield J.A., Beck K.E., Tran K., et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 2005;28(6):593-98.
  8. Min L., Vaidya A., Becker C. Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series. Endocr Pract. 2012;18:351-55. doi: 10.4158/EP11273.OR.
  9. Faje A.T., Sullivan R., Lawrence D., et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014;99(11):4078-85. doi: 10.1210/jc.2014-2306.
  10. Kim Y.H., Lee B.J., Lee K.J. A case of pituitary metastasis from breast cancer that presented as left visual disturbance. J Korean Neurosurg Soc. 2012;51:94-7. doi: 10.3340/jkns.2012.51.2.94.
  11. Juszczak A., Gupta A., Karavitaki N. Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: A case report and review. Eur J Endocrinol. 2012;167:1-5. doi: 10.1530/EJE-12-0167.
  12. Lammert A., Schneider H.J., Bergmann T. Hypophysitis caused by ipilimumab in cancer patients: Hormone replacement or immunosuppressive therapy. Exp Clin Endocrinol Diabet. 2013;121:581-87. doi: 10.1055/s-0033-1355337.
  13. European Medicines Agency: Keytruda. EPAR. 2015. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/ medicines/003820/human_med_001886. jsp&mid=WC0b01ac058001d124. Accessed: April 14, 2016.
  14. Albarel F., Gaudy C., Castinetti F. Long-term followup of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol. 2015;172:195-204. doi: 10.1530/EJE-14-0845.
  15. Weber J.S., Gibney G.T., Yu B., et al. Survival, biomarker, and toxicity analysis of nivoiumab (NIVO) in patients that progressed on ipilimumab (IPI). J Clin Oncol. 2015;33(Suppl. 15):9055a. Doi: 10.1200/ jco.2015.33.15_suppl.9055.
  16. Torino F, Corsello S.M., Salvatori R. Endocrinological side-effects of immune checkpoint inhibitors. Curr Opin Oncol. 2016;28(4):278-87. doi: 10.1097/CC0.0000000000000293.
  17. Sznol M, Postow M.A., Davies M.J., et al. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat Rev. 2017;58:70-6. doi: 10.1016/j.ctrv.2017.06.002.
  18. Rosenkranz A.A., Slastnikova T.A., Durymanov M.O., et al. Malignant melanoma and melanocortin 1 receptor. Biochem (Mosc). 2013;78:1228-37. doi: 10.1134/S0006297913110035.
  19. Abdel-Malek Z.A., Knittel J., Kadekaro A.L., et al. The melanocortin 1 receptor and the UV response of human melanocytes - a shift in paradigm. Photochem Photobiol. 2008;84:501-8. doi: 10.1111/j.1751-1097.2008.00294.x.
  20. Harsch I.A. Hypothesis: does adrenalitis caused by immune checkpoint-inhibitors put melanoma patients at an elevated risk for recurrence? J Immunother Cancer. 2019;7:166. https://doi.org/10.1186/s40425-019-0651-8.
  21. Hägg E, Asplund K., Lithner F. Value of basal plasma cortisol assays in the assessment of pituitary-adrenal insufficiency. Clin Endocrinol. (Oxf). 1987;26:221-26. doi: 10.1111/j.1365-2265.1987.tb00780.x.
  22. Falorni A., Laureti S., De Bellis A., et al. Italian addison network study: Update of diagnostic criteria for the etiological classification of primary adrenal insufficiency. J Clin Endocrinol Metab. 2004;89:1598-604. doi: 10.1210/jc.2003-030954.
  23. Purnell J.Q, Brandon D.D., Isabelle L.M., et al. Association of 24-hour cortisol production rates, cortisol-binding globulin, and plasma-free cortisol levels with body composition, leptin levels, and aging in adult men and women. J Clin Endocrinol Metab. 2004;89:281-87. doi: 10.1210/jc.2003-030440.
  24. de Miguel Novoa P, Vela E.T., Garcia N.P, et al. (Grupo Insuficiencia Adrenal). Guidelines for the diagnosis and treatment of adrenal insufficiency in the adult. Endocrinol Nutr. 2014;61(Suppl. 1):1-35. doi: 10.1016/S1575-0922(14)73526-0.
  25. Charmandari E., Nicolaides N.C., Chrousos G.P Adrenal insufficiency. Lancet. 2014;383:2152-67. doi: 10.1016/S0140-6736(13)61684-0.
  26. Wass J.A.H., Arlt W. How to avoid precipitating an acute adrenal crisis. BMJ. 2012;345:e6333. doi: 10.1136/bmj.e6333.
  27. Dine J., Gordon R., Shames Y., et al. Immune checkpoint inhibitors: an innovation in immunotherapy for the treatment and management of patients with cancer. Asia Pac J Oncol Nurs. 2017;4(2):127-35. doi: 10.4103/apjon.apjon_4_17.
  28. Morganstein D.L., Lai Z., Spain L., et al. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clin Endocrinol. (Oxf). 2017;86(4):614-20. doi: 10.1111/cen.13297.
  29. Yonezaki K., Kobayashi T., Imachi H., et al. Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto's disease and diabetes mellitus: a case report. J Med Case Rep. 2018;12(1):171. doi: 10.1186/s13256-018-1708-x.
  30. Khan U., Rizvi H., Sano D., et al. Nivolumab induced myxedema crisis. J Immunother Cancer. 2017;5:13. doi: 10.1186/s40425-017-0213-x.
  31. Mehta R., Shah A., Almhanna K. Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy. Onco Targ Ther. 2018:11:6525-37. doi: 10.2147/OTT.S152513.
  32. Robert C., Schachter J., Long G.V, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372:2521-32. doi: 10.1056/NEJMoa1503093.
  33. Kyriacou A., Melson E., Chen W., et al. Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus? Clin Med. (bond). 2020;20(4):417-23. doi: 10.7861/clinmed.2020-0054.
  34. Min L., Vaidya A., Becker C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol. 2011;164:303-7. doi: 10.1530/EJE-10-0833.
  35. Garber J.R., Cobin R.H., Gharib H., et al. Clinical practice guidelines for hypothyroidism in adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012;18:988-1028. doi: 10.4158/EP12280.GL.
  36. Brahmer J.R., Tykodi S.S., Chow L.Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.NEngl J Med. 2012;366(26):2455-65. doi: 10.1056/NEJMoa1200694.
  37. Chia-Jen W., Feng-Cheng C., Chi-Hong C., et al. Protective Role of Programmed Death 1 Ligand 1 (PD-L1) in Nonobese Diabetic Mice. Diabet. 2008;57(7):1861-69. doi: 10.2337/db07-1260.
  38. de Filette J., Andreescu C.E., Cools F, et al. A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors. Horm Metab Res. 2019;51(3):145-56. doi: 10.1055/a-0843-3366.
  39. Stamatouli A.M., Quandt Z., Perdigoto A.L., et al. Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabet. 2018;67(8):1471-80. doi: 10.2337/dbi18-0002.
  40. Brahmer J.R., Lacchetti C., Schneider B.J. National Comprehensive Cancer Network (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714-68. doi: 10.1200/jco.2017.77.6385.
  41. National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) 5.0. Available at: https://ctep.cancer.gov/protocol_Development/electronic_applications/ctc.htm.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2020

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>